LAKEFRONT BIOTHERAPEUTICS NV
Last · XETRA€26.06-0.08 (-0.31%)close · yahoo · 6h ago
Market cap€1.7B65.5M sh
P/E · TTM2.9fwd — · eps 8.88
Beta0.06vs S&P 500
Div yield0.00%annual · TTM
52w range
€22.84€44.47
Volume584session
| Revenue | €1.1B |
|---|---|
| Operating income | €295.0M |
| Net income | €320.9M |
| Free cash flow | €-271.2M |
| Operating margin | 26.5% |
| Net margin | 28.9% |
| Return on equity | 9.9% |
| Period | 2025 |
Loading chart…
OpenFilings analyst
Our analyst
From latest ANNUAL · 2026-04-07
- Operating Cf Burn
- Cash Runway Low
- Rd Intensity High
Red flags
- Operating Cf Burn — Negative operating cash flow
- Cash Runway Low — Cash runway ~0.3 years
- Rd Intensity High — R&D/Revenue 41.3%
Upcoming earnings
4:30 PM UTC+1
Period
Sep 2026
Est. EPS
—
Est. revenue
41.2M
Earnings transcripts
- Issuer IR
Q1 2026 transcript
Lakefront Biotherapeutics NV
- Issuer webcast
Webcast
Lakefront Biotherapeutics NV
- Issuer webcast
Webcast
Lakefront Biotherapeutics NV
- Issuer IR
Galapagos Conference Call transcript
Lakefront Biotherapeutics NV
- Issuer webcast
Webcast
Lakefront Biotherapeutics NV
- Issuer webcast
1840830
Lakefront Biotherapeutics NV
Press & signals
- GlobeNewswire
Lakefront Receives Transparency Notification from Bank of America
- GlobeNewswire
Acquisition of Own Shares
- GlobeNewswire
Acquisition of Own Shares
The rest of this company's wire — with summaries and source links — is part of Pro.
See plansDocuments
FormReporting forFiledFlags